Search Results

Astellas Pharma Inc. announced the opening of a new $90 million, state-of-the-art center at 480 Forbes Boulevard in South San Francisco, CA.

Myeloid Therapeutics, Inc., a clinical-stage mRNA-immunotherapy company, announced that it will collaborate with the New South Wales Government in Australia to create a world-class RNA manufacturing and research facility.

Parse Biosciences today announced an agreement with Bogotá, Colombia-based Gencell Pharma to extend Parse’s reach in Colombia specifically and also across South America.

Antengene Corporation Limited announced that South Korea’s National Health Insurance Service has approved the reimbursement of XPOVIO® for the treatment of adult patients with relapsed or refractory multiple myeloma.

Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, announced that its founder, president and chief executive officer, Derek Maetzold, has been named by Ernst & Young LLP as an Entrepreneur Of The Year® 2024 Gulf South Award winner.

Tiba Biotech , a preclinical biopharmaceutical company, today announced it has entered into a five-year, multi-million US dollar agreement with the Australian state government of New South Wales (NSW) to develop next-generation mRNA vaccines against emergency animal diseases that threaten Australia’s livestock industry and domestic food security.

Makana™ Therapeutics, a global leader in the field of xenotransplantation, was granted an important patent in South Korea that will catalyze xenotransplantation efforts in that country, the company announced.